Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David James

Showing results (681-690 of 693) with videos related to

Pageof 70
Sort By:
Science Translational Medicine|March 11, 2021
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastomaPriya Kumthekar, Caroline H Ko, Tatjana Paunesku, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2026
Predicting decompensation in unresectable hepatocellular carcinoma on atezolizumab plus bevacizumab: the ARTE ScoreLorenzo Canova, Eleonora Alimenti, Lorenzo Argiento, et al.
Journal of Hepatocellular Carcinoma|April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and BevacizumabBernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real studyCiro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.
The Lancet. Oncology|November 11, 2023
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective studyQinghe Zeng, Christophe Klein, Stefano Caruso, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET FusionMihaela Aldea, Arianna Marinello, Michael Duruisseaux, et al.
Neurology|August 17, 2021
Contemporary Neuroscience Core Curriculum for Medical SchoolsDouglas J Gelb, Jeff Kraakevik, Joseph E Safdieh, et al.
Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 24, 2021
Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in KenyaAnthony O Etyang, Ruth Lucinde, Henry Karanja, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Pageof 70

Showing results (681-690 of 693) with videos related to

Sort By:
Pageof 70
Science Translational Medicine|March 11, 2021
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastomaPriya Kumthekar, Caroline H Ko, Tatjana Paunesku, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 26, 2026
Predicting decompensation in unresectable hepatocellular carcinoma on atezolizumab plus bevacizumab: the ARTE ScoreLorenzo Canova, Eleonora Alimenti, Lorenzo Argiento, et al.
Journal of Hepatocellular Carcinoma|April 9, 2025
ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and BevacizumabBernardo Stefanini, Claudia Angela Maria Fulgenzi, Bernhard Scheiner, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real studyCiro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.
The Lancet. Oncology|November 11, 2023
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective studyQinghe Zeng, Christophe Klein, Stefano Caruso, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET FusionMihaela Aldea, Arianna Marinello, Michael Duruisseaux, et al.
Neurology|August 17, 2021
Contemporary Neuroscience Core Curriculum for Medical SchoolsDouglas J Gelb, Jeff Kraakevik, Joseph E Safdieh, et al.
Journal of Hematology & Oncology|January 22, 2022
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene statusAlessio Cortellini, Raffaele Giusti, Marco Filetti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 24, 2021
Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in KenyaAnthony O Etyang, Ruth Lucinde, Henry Karanja, et al.
European Journal of Cancer (Oxford, England : 1990)|April 24, 2026
Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinomaPei-Chang Lee, Alessio Cortellini, Bernardo Stefanini, et al.
Pageof 70